Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1984 1
1987 1
1989 1
1991 1
1992 1
1994 1
1995 1
2000 4
2003 1
2005 1
2007 1
2008 2
2009 2
2010 5
2011 4
2012 5
2013 6
2014 3
2015 2
2016 6
2018 4
2019 5
2020 1
2021 8
2022 8
2023 8
2024 11
2025 12
2026 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

102 results

Results by year

Filters applied: . Clear all
Page 1
PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer.
Patel JD, Socinski MA, Garon EB, Reynolds CH, Spigel DR, Olsen MR, Hermann RC, Jotte RM, Beck T, Richards DA, Guba SC, Liu J, Frimodt-Moller B, John WJ, Obasaju CK, Pennella EJ, Bonomi P, Govindan R. Patel JD, et al. Among authors: bonomi p. J Clin Oncol. 2013 Dec 1;31(34):4349-57. doi: 10.1200/JCO.2012.47.9626. Epub 2013 Oct 21. J Clin Oncol. 2013. PMID: 24145346 Free PMC article. Clinical Trial.
PATIENTS AND METHODS: Patients with previously untreated stage IIIB or IV nonsquamous NSCLC and Eastern Cooperative Oncology Group performance status of 0 to 1 were randomly assigned to receive pemetrexed 500 mg/m(2) or paclitaxel 200 mg/m(2) combined with carboplat …
PATIENTS AND METHODS: Patients with previously untreated stage IIIB or IV nonsquamous NSCLC and Eastern Cooperative Oncology Group performan …
Phase II Multi-institutional Clinical Trial Result of Concurrent Cetuximab and Nivolumab in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma.
Chung CH, Li J, Steuer CE, Bhateja P, Johnson M, Masannat J, Poole MI, Song F, Hernandez-Prera JC, Molina H, Wenig BM, Kumar S, Kuperwasser C, Stephens PJ, Farinhas JM, Shin DM, Kish JA, Muzaffar J, Kirtane K, Rocco JW, Schell MJ, Saba NF, Bonomi M. Chung CH, et al. Among authors: bonomi m. Clin Cancer Res. 2022 Jun 1;28(11):2329-2338. doi: 10.1158/1078-0432.CCR-21-3849. Clin Cancer Res. 2022. PMID: 35344035 Free PMC article. Clinical Trial.
Median OS in the 45 patients who had prior therapy for R/M HNSCC (cohort A) was 11.4 months, with a 1 year OS 50% [90% confidence interval (CI), 0.43-0.57]. ...CONCLUSIONS: The combination of cetuximab and nivolumab is effective in patients with both previously treated and …
Median OS in the 45 patients who had prior therapy for R/M HNSCC (cohort A) was 11.4 months, with a 1 year OS 50% [90% confidence int …
Autoantibodies against a subunit of mitochondrial respiratory chain complex I in inclusion body myositis.
Notarnicola A, Hellstrom C, Horuluoglu B, Pin E, Preger C, Bonomi F, De Paepe B, De Bleecker JL, Van der Kooi AJ, De Visser M, Sacconi S, Machado P, Badrising UA, Rietveld A, Pruijn G, Rothwell S, Lilleker JB, Chinoy H, Benveniste O, Svenungsson E, Idborg H, Jakobsson PJ, Nilsson P, Lundberg IE. Notarnicola A, et al. Among authors: bonomi f. J Autoimmun. 2024 Dec;149:103332. doi: 10.1016/j.jaut.2024.103332. Epub 2024 Nov 18. J Autoimmun. 2024. PMID: 39561568
In the validation study, anti-NDUFA11 autoantibodies were detected in 10/287 IBM patients (3.5 %), 0/29 p.m. and 0/30 DM patients. Reactivity against NDUFA11 could be confirmed by Western blot. ...
In the validation study, anti-NDUFA11 autoantibodies were detected in 10/287 IBM patients (3.5 %), 0/29 p.m. and 0/30 DM patients. Re …
Enhanced sampling in the well-tempered ensemble.
Bonomi M, Parrinello M. Bonomi M, et al. Phys Rev Lett. 2010 May 14;104(19):190601. doi: 10.1103/PhysRevLett.104.190601. Epub 2010 May 10. Phys Rev Lett. 2010. PMID: 20866953
Unbiased Boltzmann averages are computed on the fly by a recently developed reweighting method [M. Bonomi, J. Comput. Chem. 30, 1615 (2009)]. We apply WTE and its parallel tempering variant to the 2d Ising model and to a Go model of HIV protease, demonstrating in these two …
Unbiased Boltzmann averages are computed on the fly by a recently developed reweighting method [M. Bonomi, J. Comput. Chem. 30, 1615 …
CAR+ and CAR- T cells share a differentiation trajectory into an NK-like subset after CD19 CAR T cell infusion in patients with B cell malignancies.
Louie RHY, Cai C, Samir J, Singh M, Deveson IW, Ferguson JM, Amos TG, McGuire HM, Gowrishankar K, Adikari T, Balderas R, Bonomi M, Ruella M, Bishop D, Gottlieb D, Blyth E, Micklethwaite K, Luciani F. Louie RHY, et al. Among authors: bonomi m. Nat Commun. 2023 Nov 27;14(1):7767. doi: 10.1038/s41467-023-43656-7. Nat Commun. 2023. PMID: 38012187 Free PMC article.
Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial.
Pinto C, Zucali PA, Pagano M, Grosso F, Pasello G, Garassino MC, Tiseo M, Soto Parra H, Grossi F, Cappuzzo F, de Marinis F, Pedrazzoli P, Bonomi M, Gianoncelli L, Perrino M, Santoro A, Zanelli F, Bonelli C, Maconi A, Frega S, Gervasi E, Boni L, Ceresoli GL. Pinto C, et al. Among authors: bonomi m. Lancet Oncol. 2021 Oct;22(10):1438-1447. doi: 10.1016/S1470-2045(21)00404-6. Epub 2021 Sep 6. Lancet Oncol. 2021. PMID: 34499874 Clinical Trial.
Patients were randomly assigned (1:1) to receive intravenous gemcitabine 1000 mg/m(2) on days 1 and 8 every 3 weeks plus either intravenous placebo (gemcitabine plus placebo group) or ramucirumab 10 mg/kg (gemcitabine plus ramucirumab group) on day 1 every 3 weeks, until t …
Patients were randomly assigned (1:1) to receive intravenous gemcitabine 1000 mg/m(2) on days 1 and 8 every 3 weeks plus either intra …
Randomized phase 2 trial of pembrolizumab alone or in combination with low dose chemotherapy for patients with non-small cell lung cancer and poor performance status.
Addo S, Lycan T, Soto-Pantoja DR, Tsai YT, Stoen E, Ahmed T, Evans JK, Hart L, Ruiz J, Triozzi P, Bonomi M, Petty WJ. Addo S, et al. Among authors: bonomi m. Lung Cancer. 2025 May;203:108513. doi: 10.1016/j.lungcan.2025.108513. Epub 2025 Mar 27. Lung Cancer. 2025. PMID: 40203764 Free PMC article. Clinical Trial.
PATIENTS AND METHODS: Patients with advanced NSCLC and an Eastern Cooperative Oncology Group performance status (PS) of 2 were randomized to single-agent pembrolizumab at 200 mg every 3 weeks (Arm A) or the same dose of pembrolizumab combined with weekly carboplatin area under th …
PATIENTS AND METHODS: Patients with advanced NSCLC and an Eastern Cooperative Oncology Group performance status (PS) of 2 were randomized to …
Frequency of weight and body composition increases in advanced non-small cell lung cancer patients during first line therapy.
Bonomi P, Moudgalya H, Gomez SL, Shah P, Basu S, Batus M, Martinka LB, Abdelkader A, Tzameli I, Cobain S, Collins S, Keliher EJ, Breen DM, Calle RA, Fidler MJ, Borgia JA. Bonomi P, et al. J Cachexia Sarcopenia Muscle. 2024 Dec;15(6):2311-2322. doi: 10.1002/jcsm.13534. Epub 2024 Sep 17. J Cachexia Sarcopenia Muscle. 2024. PMID: 39289919 Free PMC article.
Anamorelin Efficacy in Non-Small-Cell Lung Cancer Patients With Cachexia: Insights From ROMANA 1 and ROMANA 2.
Laird BJA, Skipworth R, Bonomi PD, Fallon M, Kaasa S, Giorgino R, McMillan DC, Currow DC. Laird BJA, et al. Among authors: bonomi pd. J Cachexia Sarcopenia Muscle. 2025 Feb;16(1):e13732. doi: 10.1002/jcsm.13732. J Cachexia Sarcopenia Muscle. 2025. PMID: 39992021 Free PMC article. Clinical Trial.

METHODS: ROMANA 1 and ROMANA 2 were double-blind, placebo-controlled, randomised Phase 3 trials that enrolled people with inoperable stage III/IV NSCLC with cachexia ( 5% weight loss within 6 months or body mass index [BMI] < 20 kg/m(2)). Patients were randomised 2:1 t

…
METHODS: ROMANA 1 and ROMANA 2 were double-blind, placebo-controlled, randomised Phase 3 trials that enrolled people with inoperable stage I …
102 results